23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

  • Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.